ProteinQure, a Toronto, Canada-based protein therapeutics company, raised $4M in seed funding.
The round was led by Felicis Ventures with participation from 8VC, Golden Ventures, iNovia, Global Founders Capital and angel investor Tom Williams.
The company intends to use the funds to continue adding top interdisciplinary talent to its team and expanding its partnerships with industry leaders.
Led by Lucas Siow, CEO, Tomas Babej, CTO, Chris Ing, CSO, and Mark Fingerhuth, Head of R&D, ProteinQure provides computational R&D tools to perform drug design in silico leveraging quantum computing, molecular simulations and reinforcement learning to engineer novel therapeutics.
The company’s computational platform combines biophysical models with statistical and machine learning approaches, leverages new and upcoming advances in computing architectures, from high-performance GPUs, TPUs, and specialized circuits, all the way to quantum computers.
It is also integrating experimental data and assays to complement the computational platform.
This integrative method allows ProteinQure to learn complex underlying relationships and scale simulations of them.
The company has begun applying the platform in initial collaborations with industry leaders in the discovery of protein therapeutics. Over the next two years, they will work with these teams to generate additional data on the value of these novel approaches to peptide (small proteins) drug discovery.